The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.

Boye KS, Lebrec J, Dib A, Heitmann E, Federici MO, Yu M, Sapin H, Barrett A, Guerci B, Giorgino F, Füchtenbusch M, García-Pérez LE

Diabetes, obesity & metabolism15 Sept 2023Cited by 5 (Europe PMC)

PMID37712754DOI10.1111/dom.15145PepBankPUB-37712754

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes starting an injectable, patient-reported outcome scores improved from baseline among people who started liraglutide.
In plain wordsIn adults with type 2 diabetes, patient-reported outcomes improved from baseline in people who started liraglutide.
Peptide
Liraglutide
Outcome
Direction not reportedPatient-reported outcome scores
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Overall, improvements from baseline in PRO scores were observed among people who started dulaglutide or liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Report a problemFND-3771275401
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, treatment satisfaction improved less with liraglutide than with dulaglutide, with significant differences between cohorts at 12, 18 and 24 months.
In plain wordsIn adults with type 2 diabetes, treatment satisfaction improved less with liraglutide than with dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseTreatment satisfaction
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
A more pronounced trend of improvement was observed in the dulaglutide cohort for changes from baseline in treatment satisfaction and impact of weight on self-perception, supported by statistically significant differences between treatment cohorts in additional comparative analyses at 12, 18 and 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Report a problemFND-3771275402
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the impact of weight on self-perception improved less with liraglutide than with dulaglutide, with significant differences between cohorts at 12, 18 and 24 months.
In plain wordsIn adults with type 2 diabetes, how weight affected self-perception improved less with liraglutide than with dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseImpact of weight on self-perception
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
A more pronounced trend of improvement was observed in the dulaglutide cohort for changes from baseline in treatment satisfaction and impact of weight on self-perception, supported by statistically significant differences between treatment cohorts in additional comparative analyses at 12, 18 and 24 months.
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Report a problemFND-3771275403
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, patient perceptions of the injection device were less positive with liraglutide than with dulaglutide.
In plain wordsIn adults with type 2 diabetes, patients rated the liraglutide injection device less positively than the dulaglutide device.
Peptide
Liraglutide
Outcome
DecreasePatient perception of the injection device
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
More positive patient perceptions of the injection device were observed with dulaglutide than with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Report a problemFND-3771275404
05HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to improved overall patient-reported outcome scores from baseline.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to improved patient-reported scores from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePatient-reported outcome scores
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
Overall, improvements from baseline in PRO scores were observed among people who started dulaglutide or liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Summary · context
Adults with a T2D diagnosis, naïve to injectable treatment for T2D and prescribed dulaglutide or liraglutide as their first injectable GLM, were eligible for inclusion.
Report a problemFND-3771275405
06HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide was linked to greater treatment satisfaction improvement than liraglutide at 12, 18 and 24 months.
In plain wordsIn adults with diabetes, dulaglutide was linked to greater satisfaction improvement than liraglutide at 12, 18 and 24 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTreatment satisfaction
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
A more pronounced trend of improvement was observed in the dulaglutide cohort for changes from baseline in treatment satisfaction and impact of weight on self-perception, supported by statistically significant differences between treatment cohorts in additional comparative analyses at 12, 18 and 24 months.
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Summary · context
Adults with a T2D diagnosis, naïve to injectable treatment for T2D and prescribed dulaglutide or liraglutide as their first injectable GLM, were eligible for inclusion.
Report a problemFND-3771275406
07HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide was linked to greater improvement in weight-related self-perception than liraglutide at 12, 18 and 24 months.
In plain wordsIn adults with diabetes, weight-related self-perception improved more with dulaglutide than liraglutide at 12, 18 and 24 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseImpact of weight on self-perception
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Quality of life · Whole body
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Source sentences
Summary
A more pronounced trend of improvement was observed in the dulaglutide cohort for changes from baseline in treatment satisfaction and impact of weight on self-perception, supported by statistically significant differences between treatment cohorts in additional comparative analyses at 12, 18 and 24 months.
2 context sentences(design, population, supporting numbers)
Summary · context
TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy.
Summary · context
Adults with a T2D diagnosis, naïve to injectable treatment for T2D and prescribed dulaglutide or liraglutide as their first injectable GLM, were eligible for inclusion.
Report a problemFND-3771275407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords